Latest Rosalind Advisors, Inc. Stock Portfolio
Rosalind Advisors, Inc. Performance:
2024 Q3: 11.16%YTD: 5.12%
Performance for 2024 Q3 is 11.16%, and YTD is 5.12%.
About Rosalind Advisors, Inc. and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Rosalind Advisors, Inc. reported an equity portfolio of $156.2 Millions as of 30 Sep, 2024.
The top stock holdings of Rosalind Advisors, Inc. are DCTH, MYO, CRMD. The fund has invested 13.6% of it's portfolio in DELCATH SYSTEMS, INC. and 7.8% of portfolio in MYOMO INC.
The fund managers got completely rid off VIRIDIAN THERAPEUTICS INC (VRDN), REZOLUTE INC (RZLT) and GERON CORP (GERN) stocks. They significantly reduced their stock positions in CLEARSIDE BIOMEDICAL INC (CLSD), CYBIN INC (CYBN) and ABIVAX SA. Rosalind Advisors, Inc. opened new stock positions in CORMEDIX INC (CRMD), OWLET INC (OWLT) and VOR BIOPHARMA INC (VOR). The fund showed a lot of confidence in some stocks as they added substantially to POLYPID LTD, CELLECTAR BIOSCIENCES INC (CLRB) and OCULAR THERAPEUTIX, INC (OCUL).
The top stock holdings of Rosalind Advisors, Inc. are DCTH, MYO, CRMD. The fund has invested 13.6% of it's portfolio in DELCATH SYSTEMS, INC. and 7.8% of portfolio in MYOMO INC.
The fund managers got completely rid off VIRIDIAN THERAPEUTICS INC (VRDN), REZOLUTE INC (RZLT) and GERON CORP (GERN) stocks. They significantly reduced their stock positions in CLEARSIDE BIOMEDICAL INC (CLSD), CYBIN INC (CYBN) and ABIVAX SA. Rosalind Advisors, Inc. opened new stock positions in CORMEDIX INC (CRMD), OWLET INC (OWLT) and VOR BIOPHARMA INC (VOR). The fund showed a lot of confidence in some stocks as they added substantially to POLYPID LTD, CELLECTAR BIOSCIENCES INC (CLRB) and OCULAR THERAPEUTIX, INC (OCUL).
Rosalind Advisors, Inc. Annual Return Estimates Vs S&P 500
Our best estimate is that Rosalind Advisors, Inc. made a return of 11.16% in the last quarter. In trailing 12 months, it's portfolio return was 52.37%.
New Buys
| Ticker | $ Bought |
|---|---|
| cormedix inc | 11,918,000 |
| owlet inc | 1,212,300 |
| vor biopharma inc | 53,680 |
New stocks bought by Rosalind Advisors, Inc.
Additions
| Ticker | % Inc. |
|---|---|
| polypid ltd | 62.95 |
| cellectar biosciences inc | 35.7 |
| mediwound ltd | 22.31 |
| ocular therapeutix, inc | 18.00 |
| myomo inc | 13.37 |
| verona pharma plc | 10.00 |
| optinose inc | 9.81 |
| compass pathways plc | 6.46 |
Additions to existing portfolio by Rosalind Advisors, Inc.
Reductions
| Ticker | % Reduced |
|---|---|
| clearside biomedical inc | -95.09 |
| cybin inc | -94.43 |
| abivax sa | -63.01 |
| trevi therapeutics inc | -46.1 |
| fortress biotech inc-new | -17.27 |
| kalvista pharmaceuticals inc | -10.1 |
| profound medical corp | -8.88 |
| journey medical corp | -7.2 |
Rosalind Advisors, Inc. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| unicycive therapeutics inc | -787,328 |
| spruce biosciences inc | -780,908 |
| lyra therapeutics inc | -286,321 |
| beyond air inc | -485,511 |
| viridian therapeutics inc | -3,903,000 |
| rezolute inc | -1,075,000 |
| geron corp | -848,000 |
| bioxcel therapeutics inc | -50,780 |
Rosalind Advisors, Inc. got rid off the above stocks
Sector Distribution
Rosalind Advisors, Inc. has about 80.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 80.9 |
| Others | 19.1 |
Market Cap. Distribution
Rosalind Advisors, Inc. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MICRO-CAP | 56.2 |
| UNALLOCATED | 19.2 |
| SMALL-CAP | 16.6 |
| MID-CAP | 5.2 |
| NANO-CAP | 2.8 |
Stocks belong to which Index?
About 28.2% of the stocks held by Rosalind Advisors, Inc. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 71.8 |
| RUSSELL 2000 | 28.2 |
Rosalind Advisors, Inc. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Rosalind Advisors, Inc.
Rosalind Advisors, Inc. has 29 stocks in it's portfolio. About 70.4% of the portfolio is in top 10 stocks. OPTN proved to be the most loss making stock for the portfolio. DCTH was the most profitable stock for Rosalind Advisors, Inc. last quarter.
Last Reported on: 30 Oct, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABEO | abeona therapeutics-new | 7.41 | 1,832,000 | 11,578,200 | added | 4.69 | ||
| ACRX | talphera inc | 0.42 | 758,966 | 650,130 | unchanged | 0.00 | ||
| BFRI | biofrontera inc | 0.42 | 495,490 | 659,002 | reduced | -1.74 | ||
| BTAI | bioxcel therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CLRB | cellectar biosciences inc | 5.03 | 3,671,550 | 7,857,120 | added | 35.7 | ||
| CLSD | clearside biomedical inc | 0.10 | 127,220 | 161,569 | reduced | -95.09 | ||
| CMPS | compass pathways plc | 3.15 | 781,423 | 4,922,960 | added | 6.46 | ||
| CRMD | cormedix inc | 7.63 | 1,475,000 | 11,918,000 | new | |||
| CYBN | cybin inc | 6.12 | 1,075,100 | 9,557,680 | reduced | -94.43 | ||
| DCTH | delcath systems, inc. | 13.57 | 2,650,390 | 21,203,100 | unchanged | 0.00 | ||
| DERM | journey medical corp | 0.38 | 105,917 | 598,431 | reduced | -7.2 | ||
| FBIO | fortress biotech inc-new | 0.47 | 502,828 | 726,586 | reduced | -17.27 | ||
| GERN | geron corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KALV | kalvista pharmaceuticals inc | 2.25 | 303,864 | 3,518,740 | reduced | -10.1 | ||
| KPRX | kiora pharmaceuticals inc | 0.60 | 255,555 | 935,331 | unchanged | 0.00 | ||
| LYRA | lyra therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MYO | myomo inc | 7.76 | 3,021,390 | 12,115,800 | added | 13.37 | ||
| NAMS | newamsterdam pharma co nv | 0.11 | 10,123 | 168,042 | unchanged | 0.00 | ||
| NSPR | inspiremd inc | 4.31 | 2,514,050 | 6,737,640 | added | 0.02 | ||
| OCUL | ocular therapeutix, inc | 4.93 | 885,000 | 7,699,500 | added | 18.00 | ||